Head-to-head · Value Score
Trimi Health vs Mevo Health
Two GLP-1 deals, scored on the same six factors. Trimi Health lands a Value Score of 89, Mevo Health a 72. Here's who gives you the honest lower price — and where each one bites back.
Trimi Health
#3 · Grade A · Great Deal
Est. first month
$99/mo
Save ~93% vs brand-nameMevo Health
#198 · Grade C · Watch List
Est. first month
From $199/mo (all doses, compounded)
Save ~85% vs brand-nameThe verdict
Trimi Health takes it on Value Score, 89 to 72 — an est. $99/mo first month, with no teaser step-up baked in. Mevo Health isn't out of it: Shoppers who want physician-network GLP-1 in injection and oral-tablet forms.
Deal-by-deal
The numbers that decide it. Green ✓ marks the stronger side on each line.
| Deal | Trimi Health | Mevo Health |
|---|---|---|
| Value Score | 89 (A) | 72 (C) |
| Est. first month | $99/mo | From $199/mo (all doses, compounded) |
| Save vs brand-name | ~93% | ~85% |
| Semaglutide | $99/mo | From $199/mo (all doses, compounded) |
| Tirzepatide | $125/mo | From $259/mo (all doses, compounded) |
| Both molecules | Yes | Yes |
| Pricing | Flat — no step-up | Watch |
| Coverage | All 50 states | Coverage not published |
Factor by factor
The six factors behind each Value Score. The orange bar marks the stronger side. See the methodology.
Trimi Health
The ultra-budget pick: two-digit semaglutide and a $125 tirzepatide — one of the lowest flat tirz stickers on the whole board — shipped to all 50 states.
Why it's a deal
- Ultra-budget on both molecules — $99 semaglutide and a class-low $125 tirzepatide, flat with no teaser step-up
- Tirzepatide at $125/mo undercuts most of the flat-fee field on the priciest molecule
- Nationwide 50-state reach, so the low price isn't gated to a handful of states
The fine print
- Not LegitScript-certified — do your own pharmacy diligence before you buy on price alone
- Compounded injectable only — no FDA-approved brand-name or oral/sublingual route
- Newer brand with a thin public track record
Mevo Health
Mevo Health (Mevo Health LLC, Delaware) is a direct-pay telehealth platform offering compounded semaglutide and tirzepatide in both injection and oral-tablet forms — a rare both-routes, both-molecules menu.
Why it's a deal
- LegitScript verification badge on multiple pages
- Publishes the FDA compounded-medication disclaimer
- Four named board-certified physicians disclosed (Wasef, Suppa, Sakla, Chikando)
- Both semaglutide and tirzepatide in injection and oral-tablet forms — rare in DTC
- Public entry-level pricing surfaced
The fine print
- States served not listed on any public page
- Pharmacy partners not named (only '503A U.S. compounding pharmacies' with unlabeled logos)
- No formal Medical Director role disclosed
- Only 'as low as' entry pricing shown — no per-dose itemization
- No SOC 2 certification claimed
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes a Value Score.
Neither one the right fit? Every program that outscores Trimi Health is ranked on the Trimi Health alternatives board, and the same list for the other side is on alternatives to Mevo Health.
More head-to-heads
Prices, states and verification reflect each program's public disclosures at last check; the Value Score is our editorial judgment per the methodology. “Save vs brand-name” compares the lowest disclosed monthly price against a ~$1,349/mo brand-name cash reference. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.